BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 12546269)

  • 1. Risedronate prevents hip fractures, but who should get therapy?
    Deal CL
    Cleve Clin J Med; 2002 Dec; 69(12):964, 968-70, 973-6. PubMed ID: 12546269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures].
    Netelenbos JC
    Ned Tijdschr Geneeskd; 2001 Jul; 145(28):1336-8. PubMed ID: 11484428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.
    McClung MR; Geusens P; Miller PD; Zippel H; Bensen WG; Roux C; Adami S; Fogelman I; Diamond T; Eastell R; Meunier PJ; Reginster JY;
    N Engl J Med; 2001 Feb; 344(5):333-40. PubMed ID: 11172164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: does site-specificity exist?
    Compston JE
    Bone; 2000 Dec; 27(6):765-8. PubMed ID: 11113386
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.
    Lindsay R; Watts NB; Lange JL; Delmas PD; Silverman SL
    Osteoporos Int; 2013 Aug; 24(8):2345-52. PubMed ID: 23612793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study.
    Silverman SL; Watts NB; Delmas PD; Lange JL; Lindsay R
    Osteoporos Int; 2007 Jan; 18(1):25-34. PubMed ID: 17106785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
    Abelson A; Ringe JD; Gold DT; Lange JL; Thomas T
    Osteoporos Int; 2010 Jun; 21(6):1021-9. PubMed ID: 19722103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risedronate therapy for prevention of hip fracture after stroke in elderly women.
    Poole KE; Warburton EA; Reeve J
    Neurology; 2005 Nov; 65(9):1513-4; author reply 1513-4. PubMed ID: 16275859
    [No Abstract]   [Full Text] [Related]  

  • 10. Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date.
    Hodsman AB; Hanley DA; Josse R
    CMAJ; 2002 May; 166(11):1426-30. PubMed ID: 12054412
    [No Abstract]   [Full Text] [Related]  

  • 11. Risedronate treatment and extended fracture protection in postmenopausal women.
    Harris ST
    Clin Exp Rheumatol; 2001; 19(6):625-6. PubMed ID: 11791630
    [No Abstract]   [Full Text] [Related]  

  • 12. Risedronate increases bone mineral density and reduces the vertebral fracture incidence in postmenopausal women.
    Reginster JY
    Clin Exp Rheumatol; 2001; 19(2):121-2. PubMed ID: 11326471
    [No Abstract]   [Full Text] [Related]  

  • 13. Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.
    Berto P; Maggi S; Noale M; Lopatriello S
    Aging Clin Exp Res; 2010 Apr; 22(2):179-88. PubMed ID: 20145427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial.
    Sato Y; Kanoko T; Satoh K; Iwamoto J
    Arch Intern Med; 2005 Aug 8-22; 165(15):1737-42. PubMed ID: 16087821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomic analysis of osteoporosis treatment with risedronate.
    Brecht JG; Kruse HP; Felsenberg D; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2003; 23(4):93-105. PubMed ID: 15224498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP
    Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke.
    Sato Y; Iwamoto J; Kanoko T; Satoh K
    Arch Intern Med; 2005 Aug 8-22; 165(15):1743-8. PubMed ID: 16087822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
    Reginster J; Minne HW; Sorensen OH; Hooper M; Roux C; Brandi ML; Lund B; Ethgen D; Pack S; Roumagnac I; Eastell R
    Osteoporos Int; 2000; 11(1):83-91. PubMed ID: 10663363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing hip fracture risk with risedronate in elderly women with established osteoporosis.
    Masud T; McClung M; Geusens P
    Clin Interv Aging; 2009; 4():445-9. PubMed ID: 19966913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risedronate for the prevention and treatment of postmenopausal osteoporosis.
    Cranney A; Waldegger L; Zytaruk N; Shea B; Weaver B; Papaioannou A; Robinson V; Wells G; Tugwell P; Adachi JD; Guyatt G
    Cochrane Database Syst Rev; 2003; (4):CD004523. PubMed ID: 14584020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.